Literature DB >> 22205660

Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.

Catrin E Moore1, Branwen J Hennig, Kirsten P Perrett, J Claire Hoe, Sue J Lee, Helen Fletcher, Denise Brocklebank, Daniel O'Connor, Matthew D Snape, Andrew J Hall, Shelley Segal, Adrian V S Hill, Andrew J Pollard.   

Abstract

The rate of decay of antibody concentration following serogroup C meningococcal (MenC) polysaccharide-protein conjugate vaccination varies between individuals. This depends partly on vaccination age but may be influenced by human genetics. We studied 721 single nucleotide polymorphisms (SNPs) across 131 candidate genes in a first cohort of 905 Caucasians (11 to 21 years old; mean time after vaccination, 4.9 years) and 30 SNPs across 17 genes in a replication study using 155 children, aged 6 to 12 years (mean time after vaccination, 6.7 years), and 196 infants (1 year old; mean time after vaccination, 8 months). Individuals were classified as responders or nonresponders for total MenC IgG concentration and MenC serum bactericidal antibody (SBA) measurements. Associated genes were examined further for quantitative outcome measures. Fifty-nine SNPs in 37 genes were associated with IgG persistence (adjusted for age at measurement), and 56 SNPs in 36 genes were associated with SBA persistence (adjusted for age at measurement and vaccine used). Three SNPs each within the Toll-like receptor 3 (TLR3) (rs3775291, rs3775292, and rs5743312) and CD44 (rs11033013, rs353644, and rs996076) genes were associated with IgG (adjusted for age at measurement) or SBA (adjusted for age at measurement and vaccine used) persistence in the initial genetic study (P, 0.02 to 0.04). Single SNPs within the TLR3 (rs7657186) (P = 0.004 [unadjusted]) and CD44 (rs12419062) (P = 0.01 [unadjusted]) genes were associated with IgG persistence in the replication study. These results suggest that genetic polymorphisms in the TLR3 and CD44 genes are associated with the persistence of the immune response to MenC vaccines 1 to 6 years after vaccination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205660      PMCID: PMC3294616          DOI: 10.1128/CVI.05379-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  Genetic determinants of immune-response to a polysaccharide vaccine for typhoid.

Authors:  Partha P Majumder; Herman F Staats; Neeta Sarkar-Roy; Binuja Varma; Trina Ghosh; Sujit Maiti; K Narayanasamy; Carol C Whisnant; James L Stephenson; Diane K Wagener
Journal:  Hugo J       Date:  2010-03-11

Review 2.  Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.

Authors:  G A Poland; I G Ovsyannikova; R M Jacobson; D I Smith
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

Review 3.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

4.  Genetic regulation of immune responses to vaccines in early life.

Authors:  M J Newport; T Goetghebuer; H A Weiss; H Whittle; C-A Siegrist; A Marchant
Journal:  Genes Immun       Date:  2004-03       Impact factor: 2.676

Review 5.  Genetic variation in the response to vaccination.

Authors:  T G Kimman; R J Vandebriel; B Hoebee
Journal:  Community Genet       Date:  2007

6.  Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria.

Authors:  D M Ambrosino; G Schiffman; E C Gotschlich; P H Schur; G A Rosenberg; G G DeLange; E van Loghem; G R Siber
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

Review 7.  Meningococcal C conjugate vaccine: the experience in England and Wales.

Authors:  Helen Campbell; Ray Borrow; David Salisbury; Elizabeth Miller
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

8.  Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and Meningococcus polysaccharides.

Authors:  J P Pandey; H H Fudenberg; G Virella; C U Kyong; C B Loadholt; R M Galbraith; E C Gotschlich; J C Parke
Journal:  Lancet       Date:  1979-01-27       Impact factor: 79.321

9.  Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

Authors:  Matthew D Snape; Kirsten P Perrett; Karen J Ford; Tessa M John; David Pace; Ly-Mee Yu; Joanne M Langley; Shelley McNeil; Peter M Dull; Francesca Ceddia; Alessandra Anemona; Scott A Halperin; Simon Dobson; Andrew J Pollard
Journal:  JAMA       Date:  2008-01-09       Impact factor: 56.272

10.  Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.

Authors:  Branwen J Hennig; Katherine Fielding; John Broxholme; Mathurin Diatta; Maimuna Mendy; Catrin Moore; Andrew J Pollard; Pura Rayco-Solon; Giorgio Sirugo; Marianne A van der Sande; Pauline Waight; Hilton C Whittle; Syed M Zaman; Adrian V Hill; Andrew J Hall
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

View more
  8 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 2.  The role of Toll-like receptor 4 polymorphisms in vaccine immune response.

Authors:  P Pellegrino; F S Falvella; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

3.  Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth.

Authors:  Stephen A Spector; Min Qin; Jorge Lujan-Zilbermann; Kumud K Singh; Meredith G Warshaw; Paige L Williams; Patrick Jean-Philippe; Terence Fenton; George K Siberry
Journal:  Clin Vaccine Immunol       Date:  2013-04-17

4.  Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.

Authors:  Zhisheng Her; Terk-Shin Teng; Jeslin J L Tan; Teck-Hui Teo; Yiu-Wing Kam; Fok-Moon Lum; Wendy W L Lee; Christelle Gabriel; Rossella Melchiotti; Anand K Andiappan; Valeria Lulla; Aleksei Lulla; Mar K Win; Angela Chow; Subhra K Biswas; Yee-Sin Leo; Marc Lecuit; Andres Merits; Laurent Rénia; Lisa F P Ng
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

Review 5.  The genetic regulation of infant immune responses to vaccination.

Authors:  Melanie J Newport
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

Review 6.  N. meningitidis and TLR Polymorphisms: A Fascinating Immunomodulatory Network.

Authors:  Elena Gianchecchi; Alessandro Torelli; Giulia Piccini; Simona Piccirella; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2016-05-27

Review 7.  Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.

Authors:  Vince Kornél Grolmusz; Anikó Bozsik; János Papp; Attila Patócs
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

8.  Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection.

Authors:  Fumi Sato-Kaneko; Shiyin Yao; Fitzgerald S Lao; Jason Nan; Jonathan Shpigelman; Annette Cheng; Tetsuya Saito; Karen Messer; Minya Pu; Nikunj M Shukla; Howard B Cottam; Michael Chan; Anthony J Molina; Maripat Corr; Tomoko Hayashi; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.